XELODA showed a 13% improvement in 3-year DFS
compared with 5-FU/LV

XELODA delivered comparable DFS regardless of age, gender, stage, or baseline CEA.1

Although neither XELODA nor combination chemotherapy has been shown to prolong overall survival, combination chemotherapy has been demonstrated to improve DFS compared with 5-FU/LV.1

 

XELODA—Effective fluoropyrimidine foundation to achieve your goals in adjuvant colon cancer treatment

 

 

 

 

 
 
‡ 44% required dose reduction for 5-FU/LV.¹
§ Adapted from Twelves C, et al, 2005.8
|| Intent-to-treat population.
¶ XELODA vs 5-FU/LV.
# Wald chi-squared test for difference between treatment arms.

 

REFERENCES

1. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696-2704.